Myocardin

• Myocardin A Enhances Telomerase Activities in Adipose Tissue Mesenchymal Cells and Embryonic Stem Cells
• Myocardin Expression Enhances the Therapeutic Effect of Human Mesenchymal Stem Cells
• Myocardin Factors to Regulate SMC Differentiation Marker Gene Expression
• myocardin family of transcriptional coactivators
• myocardin family of transcriptional coactivators
• Myocardin Induces Cardiomyocyte Hypertrophy
• Myocardin is a bifunctional switch for smooth versus skeletal muscle differentiation
• Myocardin is a direct transcriptional target of Mef2
• Control of Phenotypic Plasticity of Smooth Muscle Cells
• Diaphanous 1 and 2 Regulate Smooth Muscle Cell Differentiation by Activating the Myocardin-Related Transcription Factors
• Dominant Driver of the Smooth Muscle Cell Contractile Phenotype
• Fibroblasts from human postmyocardial cardiomyocytes after transduction with myocardin gene
• Rac, PAK and p38 regulate cell contact-dependent nuclear translocation of myocardin-related transcription factor
• Related Transcription Factors
• Smooth muscle cell-specific transcription is regulated by nuclear localization of the myocardin
• Smooth Muscle Expression

back

Systems Biology Approaches to Metabolic and Cardiovascular Disorders

• Multi-organ whole-genome measurements and reverse engineering to uncover gene networks underlying complex traits
• A thematic review series: systems biology approaches to metabolic and cardiovascular disorders
• Lipidomics: a global approach to lipid analysis in biological systems
• Network perspectives of cardiovascular metabolism
• Approaches to lipid metabolism gene identification and characterization in the postgenomic era
• Proteomics approaches to the systems biology of cardiovascular diseases
• Reverse engineering gene networks to identify key drivers of complex disease phenotypes

back

Niacin Therapy

• Niacin Therapy
• Comprehensive Lipid Management Versus Aggressive Low-Density Lipoprotein Lowering to Reduce Cardiovascular Risk
• Evidence to Support Aggressive Management of High-Density Lipoprotein Cholesterol- Implications of Recent Imaging Trials
• Mechanism of Action of Niacin
• Niacin and Lipoprotein(a)
• Niacin Use and Cutaneous Flushing
• Nicotinic Acid, Alone and in Combinations, for Reduction of Cardiovascular Risk
• Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy
• Safety of Niacin and Simvastatin Combination Therapy
• The Safety of Niacin in the US Food and Drug Administration Adverse Event Reporting Database
• Safety Considerations with Niacin Therapy
• Nonstatins-Safety Considerations with Niacin Therapy

back

Sarcomere

• Review focus series: sarcomeric proteins as key elements in integrated control of cardiac function
• Assembly and maintenance of the sarcomere night and day
• Ca2+ exchange with troponin C and cardiac muscle dynamics
• Cardiac function and modulation of sarcomeric function by length
• Sarcomeric dysfunction in heart failure
• Sarcomeric proteins and inherited cardiomyopathies
• The role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction

back

Lipid-binding domains

• The role of electrostatics in protein–membrane interactions
• The prevalence and significance of PDZ domain–phosphoinositide interactions
• The Phox (PX) domain proteins and membrane traffic
• Sphingolipid-binding proteins
• Phosphatidylinositol 3-phosphate recognition and membrane docking by the FYVE domain
• Phosphatidic acid-and phosphatidylserine-binding proteins
• Membrane binding domains
• Membrane binding and subcellular targeting of C2 domains
• Membrane and juxtamembrane targeting by PH and PTB domains
• Live cell imaging of phosphoinositide dynamics with fluorescent protein domains
• C1 domains exposed-From diacylglycerol binding to protein–protein interactions
• BAR, F-BAR (EFC) and ENTH-ANTH domains in the regulation of membrane–cytosol interfaces and membrane curvature

  back

Acute Cardiology

• Transcriptional activity of genes encoding Transforming Growth Factor β and its receptors in peripheral blood mononuclear cells from patients with acute coronary syndromes
• The management of acute myocardial infarction in developing countries
• Serological evidence of altered collagen homeostasis reflects early ventricular remodeling following acute myocardial infarction
• QT dispersion and left ventricular function after stent placement in acute myocardial infarction
• Myocardial infarction redefined-Impact on case-load and outcome of patients with suspected acute coronary syndrome and nondiagnostic ECG at presentation
• Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties
• Inter-relationships of indices of endothelial damage-dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes
• Increasing post-event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome
• Improvement of sympathetic response to exercise by oral administration of ascorbic acid in patients after myocardial infarction
• Improvement in left ventricular function following coronary stenting in patients with acute myocardial infarction
• Improved detection of acute myocardial infarction using a diagnostic algorithm based on calculated epicardial potentials
• Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction
• Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction
• Comparison of clinical and angiographic features and longterm follow-up events between patients with variant angina and patients with ST elevation myocardial infarction
• Coagulation activation and expression of CD40 ligand on platelets upon in vitro lipopolysaccharide-challenge in patients with unstable angina
• Carotid atherosclerotic plaque instability in patients with acute myocardial infarction
• B-type natriuretic peptide as an integrated risk marker in non-ST elevation acute coronary syndromes

  back

Imaging and echocardiography

• Tissue Doppler and innovative myocardial-deformation imaging techniques for assessment of myocardial viability.
• Prognostic role of single-photon emission computed tomography (SPECT) imaging in myocardial viability.
• Prognostic role of dobutamine stress echocardiography in myocardial viability.
• Positron emission tomography for assessment of viability.
• Magnetic resonance for the assessment of myocardial viability.
• Integrated backscatter for the assessment of myocardial viability
• Contrast echocardiography for the assessment of myocardial viability.
• Assessment of myocardial viability by radionuclide and echocardiographic techniques

  back

Ingiogensis and angiogenesis

• VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype
• VEGF function in vascular pathogenesis
• Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling
• The effect of genetic diversity on angiogenesis
• Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
• Regulation of lymphangiogenesis—From cell fate determination to vessel remodeling
• Protease-mediated regulation of angiogenesis
• Pericytes and vascular stability
• Neuropilins in neoplasms-Expression, regulation, and function
• Neuronal clues to vascular guidance
• Integrins and angiogenesis
• Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression
• Endothelial cadherins and tumor angiogenesis
• Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
• Angiogenesis in the mouse retina
• Small animal models to study angiogenesis and lymphangiogenesis

  back

心肌梗塞

• Acute Myocardial Infarction
• Role of Aldosterone Blockade for Treatment of Heart Failure and Post–Acute Myocardial Infarction
• Post–Acute Myocardial Infarction Pathophysiology
• Improving Outcomes in Post–Acute Myocardial Infarction Heart Failure
• Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction
• epidemiol-Reproducible Epidemiologic Research
• The incidence of stroke after myocardial infarction
• Selective COX-2 Inhibitors and Risk of Myocardial Infarction
• Reducing Infarct Size in The Setting of Acute Myocardial Infarction
• Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction
• new definition of myocardial infarction and the impact of troponin determination on clinical practice
• Natural and Unnatural Triggers of Myocardial Infarction
• Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction
• Early reperfusion strategies after acute ST-segment elevation myocardial infarction
• Early management of ST-segment elevation myocardial infarction
• Early intervention and prevention of myocardial infarction
• Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

  back

Cerebral vascular diseases

• Introduction to the special issue on cerebral vascular diseases
• Vascular smooth muscle function-The physiology and pathology of vasoconstriction
• Sex differences and the effect of hormonal therapy on ischemic brain injury
• Protein kinase C and synaptic dysfunction after cardiac arrest
• Mechanisms of hyperbaric oxygen and neuroprotection in stroke
• Angiogenesis and stem cell transplantation as potential treatments of cerebral ischemic stroke
• Age and cerebral circulation

  back

医学信息学在心血管研究中的应用

• Use of a Patient-Accessible Electronic Medical Record in a Practice for Congestive Heart Failure
• The effect of simplifying assumptions in the bidomain model of cardiac tissue
• Satisfaction with medical information in women with hypertensive disorders
• Prospective recruitment of patients with congestive heart failure using an ad-hoc binary classifier
• Producing computer-generated tailored written information for stroke patients and their carers
• Prediction of vascular tissue engineering results with artificial neural networks
• Organizational Issues in Implementing Automated Decision Support for Hypertension in Three Medical Centers
• Monitoring Device Safety in Interventional Cardiology
• Modeling ventricular excitation
• Impact on Quality-of-Care Indicators for Acute Myocardial Infarction
• GPs' decisions on drug treatment for patients with high cholesterol values
• Experimental analysis of heart rate variability of long-recording electrocardiograms in normal subjects and patients with coronary artery disease
• Discrimination and calibration of mortality risk prediction models in interventional cardiology
• Defibrillation threshold computed from normal and supernormal excitable cardiac tissue
• Cardiovascular risk calculators-understanding differences and realising economic implications
• Automated spoken dialogue system for hypertensive patient home management
• Analysis of nursing records of cardiac-surgery patients based on the nursing process
• A systematic critique of diabetes on the world wide web for patients and their physicians
• A resistor interpretation of general anisotropic cardiac tissue
• A Record Linkage Protocol for a Diabetes Registry at Ethnically Diverse Community Health Centers
• A Randomized Trial of Electronic Clinical Reminders to Improve Quality of Care for Diabetes and Coronary Artery Disease
• A physiological model of cerebral blood flow control
• A cylindrical model for studying subendocardial ischaemia in the left ventricle
• Use of a Patient-Accessible Electronic Medical Record in a Practice for Congestive Heart Failure
• The effect of simplifying assumptions in the bidomain model of cardiac tissue
• Satisfaction with medical information in women with hypertensive disorders
• Prospective recruitment of patients with congestive heart failure using an ad-hoc binary classifier
• Producing computer-generated tailored written information for stroke patients and their carers
• Prediction of vascular tissue engineering results with artificial neural networks
• Organizational Issues in Implementing Automated Decision Support for Hypertension in Three Medical Centers
• Monitoring Device Safety in Interventional Cardiology
• Modeling ventricular excitation
• Modeling of arterial stenosis and its applications to blood diseases
• Impact on Quality-of-Care Indicators for Acute Myocardial Infarction
• Experimental analysis of heart rate variability of long-recording electrocardiograms in normal subjects and patients with coronary artery disease
• Discrimination and calibration of mortality risk prediction models in interventional cardiology
• Defibrillation threshold computed from normal and supernormal excitable cardiac tissue
• Cardiovascular risk calculators-understanding differences and realising economic implications
• Automated spoken dialogue system for hypertensive patient home management
• Analysis of nursing records of cardiac-surgery patients based on the nursing process
• A systematic critique of diabetes on the world wide web for patients and their physicians
• A resistor interpretation of general anisotropic cardiac tissue
• A Record Linkage Protocol for a Diabetes Registry at Ethnically Diverse Community Health Centers
• A Randomized Trial of Electronic Clinical Reminders to Improve Quality of Care for Diabetes and Coronary Artery Disease
• A physiological model of cerebral blood flow control
• A cylindrical model for studying subendocardial ischaemia in the left ventricle
• HeartScore(R)-a new web-based approach to European cardiovascular disease risk management
• The Evolution of the Discipline of Vascular Biology-From Systems Physiology to Molecular Biology to Molecular Systems
• Arrhythmogenic right ventricular cardiomyopathy-clinical registry and database
• Cardiovascular risk calculators
• Dimensionality in cardiac modelling
• Simulation of ATP metabolism in cardiac excitation–contraction coupling
• Propagation of normal beats and re-entry in a computational model of ventricular cardiac tissue with regional differences
• Parameter estimation in cardiac ionic models
• Mechanistic systems models of cell signaling networks- a case study of myocyte adrenergic regulation
• gradient model of cardiac pacemaker myocytes
• Electromechanical model of excitable tissue to study reentrant cardiac arrhythmias
• Development of models of active ion transport for whole-cell modelling- cardiac sodium–potassium pump
• Approaches to modeling crossbridges and calcium-dependent activation in cardiac muscle
• Analysing cardiac excitation–contraction coupling with mathematical models of local control
• Modeling the isolated cardiac myocyte

  back

Pathogenesis of Hypertension

• Does Obesity Limit Response to Angiotensin Blockade
• Update on G-protein Polymorphisms in Hypertension
• The Link Between Glut-1 and Hypertension in Diabetic Nephropathy
• The Future of Endothelin-receptor Antagonism as Treatment for Systemic Hypertension
• Small Artery Remodeling in Hypertension and Diabetes
• Role of Hypertension in the Metabolic Syndrome
• Proximal Tubular Function and Salt Sensitivity
• Management of Hypertension and Diabetes
• Genetic Determinants of the Metabolic Syndrome
• Fat Tissue Metabolism and Adrenal Steroid Secretion
• Endothelium, Aging, and Hypertension

  back

Calcification and Cardiovascular Health

• Calcification and Cardiovascular Health-New Insights Into an Old Phenomenon
• Vitamin K epoxide reductase complex and vascular calcification-is this the important link between vitamin K and the arterial vessel wall
• Vascular calcification
• Vascular calcification-mechanisms and clinical ramifications
• Vascular calcification mechanisms
• Vascular calcification in patients with chronic kidney disease
• Vascular calcification in chronic kidney disease
• Vascular calcification and cardiovascular function in chronic kidney disease
• The role of vitamin D in vascular calcification
• Risk factors for coronary calcification in older subjects
• Regulation of vascular calcification by osteoclast regulatory factors RANKL
• Regulation of cardiovascular calcification
• Reducing the burden of cardiovascular calcification in patients with chronic kidney disease
• Proatherogenic pathways leading to vascular calcification
• Pathogenesis of vascular calcification in dialysis patients
• Novel ideas of gene therapy for atherosclerosis
• Modeling the implications of changes in vascular calcification in patients
• medicine update-hp-Alcohol and Hypertension-An Update
• Ghrelin blunted vascular calcification in vivo and in vitro in rats
• Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina-the role of GNB3 C825T polymorphism
• Effect of lipid modification on progression of coronary calcification
• Diagnostic and prognostic value of coronary artery calcium screening
• Coronary calcification improves cardiovascular risk prediction in the elderly
• Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes
• Bone morphogenetic proteins in vascular calcification
• Biology of vascular calcification in renal disease
• Atherothrombosis and high-risk plaque
• Atherosclerosis and vascular calcification in chronic renal failure
• Association of vascular 18F-FDG uptake with vascular calcification
• Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia
• Aged garlic extract retards progression of coronary artery calcification
• adrenomedullin, C-type natriuretic peptide, and parathyroid hormone-related peptide on calcification in cultured rat vascular smooth muscle cells

  back

CNS Malignancies

• Whole-Brain Radiotherapy in the Management of Brain Metastasis
• Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors
• Resectable Brain Metastases
• Recent Advances in the Treatment of Malignant Astrocytoma
• Primary CNS Lymphoma
• Physiologic and Metabolic Magnetic Resonance Imaging in Gliomas
• Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
• Diffusely Infiltrative Low-Grade Gliomas in Adults
• Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
• Current Strategies in Treatment of Oligodendroglioma
• Advances Toward an Understanding of Brainstem Gliomas

  back

Lipid Posttranslational Modifications

• Lipid modifications of proteins
• Prelamin A, Zmpste24, misshapen cell nuclei, and progeria—new evidence suggesting that protein farnesylation could be important for disease pathogenesis
• Geranylgeranylation of Rab GTPases
• Fighting parasitic disease by blocking protein farnesylation
• Farnesyl transferase inhibitors
• CAAX modification and membrane targeting of Ras
• Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I

  back

Cerebral vascular diseases

• Introduction to the special issue on cerebral vascular diseases
• Vascular smooth muscle function-The physiology and pathology of vasoconstriction
• Sex differences and the effect of hormonal therapy on ischemic brain injury
• Protein kinase C and synaptic dysfunction after cardiac arrest
• Mechanisms of hyperbaric oxygen and neuroprotection in stroke
• Angiogenesis and stem cell transplantation as potential treatments of cerebral ischemic stroke
• Age and cerebral circulation

  back

Heart Failure Practice Guideline

• HFSA 2006 Comprehensive Heart Failure Practice Guideline
• Conceptualization and Working De?nition of Heart Failure
• Electrophysiologic Testing and the Use of Devices in Heart Failure
• Disease Management in Heart Failure Education and Counseling
• Heart Failure in Patients With Left Ventricular Systolic Dysfunction
• Nonpharmacologic Management and Health Care Maintenance in Patients With Chronic Heart Failure
• Management of Asymptomatic Patients With Reduced Left Ventricular Ejection Fraction
• Evaluation of Patients for Ventricular Dysfunction and Heart Failure
• Surgical Approaches to the Treatment of Heart Failure
• Evaluation and Management of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
• Evaluation and Management of Patients With Acute Decompensated Heart Failure
• Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease
• Managing Patients With Hypertension and Heart Failure
• Management of Heart Failure in Special Populations
• Myocarditis: Current Treatment

  back

Detection of Vulnerable Plaques

• Role of Magnetic Resonance and Intravascular Magnetic Resonance in the Detection of Vulnerable Plaques
• Radionuclide Imaging for the Detection of Inflammation in Vulnerable Plaques
• Prologue-Detection of Vulnerable Plaques
• Plaque Characterization With Optical Coherence Tomography
• Pathology of the Vulnerable Plaque
• Pathogenesis of Atherosclerosis
• New Opportunities for Identification and Reduction of Coronary Risk
• Near-Infrared Spectroscopy for the Detection of Vulnerable Coronary Artery Plaques
• Intravascular Radiation Detectors for the Detection of Vulnerable Atheroma
• Intravascular Palpography for Vulnerable Plaque Assessment
• Intracoronary Thermography for Detection of High-Risk Vulnerable Plaques
• Imaging Vulnerable Plaque by Ultrasound
• Epilogue-What Do Clinicians Expect From Imagers
• C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
• Atherosclerotic Plaque Characterization by Multidetector Row Computed Tomography Angiography

  back

Pathophysiology of hypertension

• Magnesium and hypertension
• Targeting reactive oxygen species in hypertension
• Renal and vascular hypertension-induced inflammation
• Inflammation in hypertension
• Functional genomics in hypertension
• From big fat cells to high blood pressure
• Endothelial progenitor cells

  back

Apoptosis and the heart

• STRESS signaling pathways that modulate cardiac myocyte apoptosis
• reperfusion injury at the intersection with cell death
• Perindopril Regulates [beta]-Agonist-Induced Cardiac Apoptosis
• Mouse models of mitochondrial dysfunction and heart failure
• MK2 gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury
• measurement and technical issues
• Convergent signal transduction pathways controlling cardiomyocyte survival and function
• BNip3 and signal-specific programmed death in the heart
• Apoptosis of ventricular myocytes
• Apoptosis and heart failure
• Apoptosis and the heart-a decade of progress

  back

From CCU to CHF

• What can we learn from Europe
• Treatments that improve outcome in the patient with heart failure
• Towards an optimal care pathway for post-myocardial infarction heart failure
• role of nurses in the management of heart failure
• Pathophysiology of heart failure following myocardial infarction
• Lessons from the management of chronic heart failure
• Lessons from the management of acute myocardial infarction
• Heart failure post-myocardial infarction
• Epidemiology and management of heart failure
• Bridging the treatment gap
• From CCU to CHF

  back

Percutaneous coronary intervention 2005

• Percutaneous coronary intervention in unprotected left main stem disease
• Myocardial infarction centres
• Left main stem coronary disease
• Drug eluting stents
• Coronary stents
• Chronic total occlusions-a stiff challenge requiring a major breakthrough
• Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention
• Brachytherapy
• beyond stents and glycoprotein IIb-IIIa inhibitors
• Acute myocardial infarction
• Percutaneous coronary intervention 2005

  back

Fetal origins of adult disease

• Response of the fetal heart to changes in load
• Is there a fetal origin of peripheral vascular disease
• Fetal roots of cardiac disease
• The development of cardiac rhythm
• Fetal origins of adult disease

  back

Atherothrombosis

• Scientific and therapeutic advances in antiplatelet therapy
• Molecular, cellular and functional imaging of atherothrombosis
• Lovastatin and beyond
• HDL as a target in the treatment of atherosclerotic cardiovascular disease
• Heparin-induced thrombocytopenia
• Endovascular management of acute deep vein thrombosis
• Diagnostic assessment of deep vein thrombosis and pulmonary embolism
• Anticoagulants in the treatment of deep vein thrombosis
• deep vein thrombosis1

  back

Endothelial function

• The clinical implications of endothelial dysfunction
• Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure
• New methods to evaluate endothelial function
• Genetic regulation of endothelial function
• Endothelial function. From vascular biology to clinical applications
• Endothelial function and inflammation in coronary artery disease
• Endothelial function and clinical outcome
• Childhood origins of endothelial dysfunction
• Endothelial function-20 years of clinical investigation

  back

Time to Benefit in Lipid-Lowering Trials

• The Case for Intensive Statin Therapy After Acute Coronary Syndromes
• Safety of High-Dose Atorvastatin Therapy
• Review of Primary and Secondary Prevention Trials with Lovastatin, Pravastatin, and Simvastatin
• Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic Actions
• Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol
• Effect of Intensive Lipid Lowering on Progression of Coronary Atherosclerosis
• Early Time to Benefit with Intensive Statin Treatment
• Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm
• Diet, Lifestyle, and Nonstatin Trials-Review of Time to Benefit
• Time to Benefit in Lipid-Lowering Trials

  back

Marker

• The relationship between blood sugar levels and cardiovascular disease
• The long-term impact of cardiovascular risk factors on death
• Surrogate Markers for Cardiovascular Disease-Structural Markers
• Surrogate Markers for Cardiovascular Disease-Functional Markers
• Risk Factor Criteria
• Pulse pressure and inflammatory markers
• Microalbuminuria
• metabolic syndrome-an emerging risk state for cardiovascular disease
• Markers of Malign Across the Cardiovascular Continuum
• Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia
• Introduction to Surrogate Markers
• Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors
• Genetic Markers-Progress and Potential for Cardiovascular Disease
• Genetic epidemiological approaches in the study of risk factors for cardiovascular disease
• Estrogens, lipoproteins, and cardiovascular risk factors
• Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
• Comparison of low risk and higher risk profiles in middle age to frequency and quantity of coronary artery calcium
• Chlamydia pneumoniae seropositivity and cardiovascular risk factors
• Cardiovascular risk, the metabolic syndrome and the hypertriglyceridaemic
• C-reactive protein and coronary heart disease
• Body fatness and clustering of cardiovascular disease risk factors

  back

Angiogenesis inhibitors

• Tumstatin, the NC1 domain of α3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth
• Mechanisms and significance of bifunctional NK4 in cancer treatment
• Chondromodulin-I and tenomodulin
• Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
• Angioarrestin
• Angiogenesis inhibitors

  back

Cardiopulmonary monitoring

• The value of venous oximetry
• Regional carbon dioxide monitoring to assess the adequacy of tissue perfusion
• New technologies for measuring cardiac output
• Monitoring of right-sided heart function
• Monitoring of pulmonary mechanics in acute respiratory distress syndrome
• How to use central venous pressure measurements
• How monitoring of the microcirculation may help us at the bedside
• Hemodynamic assessment of critically ill patients using echocardiography Doppler

  back

KATP channels

• KATP channels-Sarcolemmal KATP channels
• KATP channels-Roles of KATP channels as metabolic sensors in acute metabolic changes
• KATP channels-Regulation of the ATP-sensitive K channel
• KATP channels-Neuroprotection by KATP channels
• KATP channels-Mitochondrial KATP channels in cell survival and death
• KATP channels-KChIP2 modulates the cell surface expression of Kv1.5-encoded K+ channels
• KATP channels-KATP channels vingt ans après
• KATP channels-KATP channel interaction with adenine nucleotides
• KATP channels-four-the biogenesis of KATP channels
• KATP channels-Cardiac KATP channels in health and disease
• KATP channels-ATP-sensitive K+ channel channel-enzyme multimer
• KATP channels-and preconditioning
• KATP channels-ABC proteins targeted by KATP channel openers
• KATP channels-a key component of the ATP-sensitive potassium channel

  back

Arterial stiffness

• Vascular stiffening and arterial compliance
• Pseudo-hypertension and arterial stiffness
• Prognostic application of arterial stiffness
• Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness
• Measurement and application of arterial stiffness in clinical research
• Large artery stiffness
• Aortic Diameter, Aortic Stiffness, and Wave Reflection Increase With Age and Isolated Systolic Hypertension
• Factors influencing arterial stiffness in systolic hypertension in the elderly
• Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases
• Coronary ischemic disease, arterial stiffness, and pulse pressure
• Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms
• Clinical applications of arterial stiffness; definitions and reference values
• Clinical applications of arterial stiffness
• Assessment of arterial stiffness in clinical practice
• Arterial stiffness in diabetes and hypertension
• Arterial stiffness and stroke in hypertension
• Arterial stiffness and pulse wave velocity
• Arterial stiffness and kidney function
• Arterial stiffness,endothelial function and novel pharmacological approaches

  back

Mineral metabolism

• Which vitamin D derivative to prescribe for renal patients
• Vascular calcification
• Role of fibroblast growth factor 23 in health and in chronic kidney disease
• Risks in dysregulation of the divalents
• Recent findings in phosphate homeostasis
• Fetuin-A and extraosseous calcification in uremia
• Editorial introductions
• Does calcitriol have actions independent from the vitamin D receptor
• Carboxyl-terminal parathyroid hormone fragments
• Calcimimetic

  back

The year in Cardiology

• A challenge to the metabolic approach to myocardial ischaemia
• Acute hyperglycaemia-a ‘new’ risk factor during myocardial infarction
• Cardiac Function and Heart Failure
• Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery
• Cardiomyopathies
• Coronary artery bypass grafting on the beating heart
• Coronary artery disease and depression
• Coronary flow
• Development of cardiovascular drugs
• Effects of Physical Activity on Serum C-Reactive Protein and Inflammatory Markers
• Fractional flow reserve and complex coronary pathologic conditions
• Isoprostanes, emerging biomarkers and potential mediators in cardiovascular diseases
• Metabolic manipulation in ischaemic heart disease
• Myocardial bridging
• Myocardial Ischemia and Infarction
• Natriuretic peptides in unstable coronary artery disease
• New aspects in the pathogenesis of diabetic atherothrombosis
• Noninvasive Imaging
• Non-invasive ultrasound in arterial wall dynamics in humans
• Nonsustained ventricular tachycardia
• Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation
• Percutaneous coronary interventions in Europe 1992–2001
• Primary hyperparathyroidism and heart disease
• Recent hypertension trials
• Reperfusion strategies for acute myocardial infarction in the elderly
• Role and importance of biochemical markers in clinical cardiology
• Terminology for high-risk and vulnerable coronary artery plaques
• The Cardiology Audit and Registration Data Standards
• The severe cardiorenal syndrome
• The year in atherothrombosis
• The year in cardiac imaging
• The Year in Cardiovascular Surgery
• The year in cardiovascular surgery
• The year in clinical electrophysiology
• The Year in Congenital Heart Disease
• The year in congenital heart disease-2003
• The year in echocardiography
• The year in electrophysiology
• The year in heart failure
• The year in interventional cardiology
• The year in valvular heart disease
• The year in valvular heart disease
• Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine
• Valvular Heart Diseas-Cardiac Surgery

  back

Metabolic and cardiovascular disease

• Metabolic and cardiovascular disease-complications and consequences
• Adiponectin
• Diabetic dyslipidaemia
• Diabetic dyslipidaemiametabolic syndrome in patients with established cardiovascular disease
• inflammation-Lipoprotein cycle
• Markers of inflammation and their clinical significance
• Target gene discovery in extended families with type 2 diabetes mellitus

  back

Preventing and Treating Thromboembolism in the 21st Century

• Stroke prevention in atrial fibrillation
• pharmacologic overview of current and emerging anticoagulants
• Heparin-induced thrombocytopenia-Principles for early recognition and management
• Current and emerging options in the management of venous thromboembolism
• Cost considerations surrounding current and future anticoagulant therapies
• Anticoagulation in special patient populations
• Preventing and Treating Thromboembolism in the 21st Century

  back

老年心血管系统

• Aging-associated changes in cardiac gene expression
• Aging,telomeres, and atherosclerosis
• Mitochondrial function and myocardial aging
• Aging hearts and vessels
• Aging-associated changes in cardiac gene expression
• Aging decreases vasoconstrictor responses of coronary resistance arterioles through endothelium-dependent mechanisms
• Vascular consequences of menopause and hormone therapy
• Protection in the aged heart
• Aging and biomedicine 2005
• Inflammatory markers and cardiovascular health in older adults
• Gene expression profiling studies of aging in cardiac and skeletal muscles
• Evolution and modulation of age-related medial elastocalcinosis
• Endothelial aging
• Aging, telomeres, and atherosclerosis
• Aging and plasminogen activator inhibitor-1 (PAI-1) regulation
• Adenosine-mediated cardioprotection in the aging myocardium
• Vascular consequences of menopause and hormone therapy
• The effects of aging and exercise training on endothelin-1 vasoconstrictor responses
• Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneoulsy hypertensive
• Protection in the aged heart
• MMP-9 regulates both positively and negatively collagen gel contraction
• Mitochondrial function and myocardial aging
• Inflammatory markers and cardiovascular health
• Heart function and molecular biological parameters are comparable in young adult and aged rats
• Sympathetic neuronal regulation of the heart in aging and heart failure
• In vivo gene transfer of parvalbumin improves diastolic function
• Gene expression profiling studies of aging in cardiac and skeletal muscles
• Exaggerated coronary vasoreactivity to endothelin-1 in aged rats
• Evolution and modulation of age-related medial elastocalcinosis
• Endothelial aging
• Cardiac-specific effects of parathyroid hormone-related peptide
• Aging hearts and vessels
• Aging and plasminogen activator inhibitor-1 (PAI-1) regulation
• Aging and biomedicine
• Age-dependent changes in myocardial matrix metalloproteinase
• Age-associated changes in electrophysiologic remodeling
• Adenosine-mediated cardioprotection in the aging myocardium
• Protection in the aged heart-preventing the heart-break of old age
• Inflammatory markers and cardiovascular health in older adults
• Gene expression profiling studies of aging in cardiac and skeletal muscles
• Aging-associated changes in cardiac gene expression
• Masters of adaptation and survival
• Adenosine-mediated cardioprotection in the aging myocardium
• Vascular consequences of menopause and hormone therapy
• Sympathetic neuronal regulation of the heart in aging and heart failure
• Protection in the aged heart
• Mitochondrial function and myocardial aging
• Inflammatory markers and cardiovascular health in older adults
• Gene expression profiling studies of aging in cardiac and skeletal muscles
• Evolution and modulation of age-related medial elastocalcinosis
• Endothelial aging
• Aging-associated changes in cardiac gene expression
• Aging, telomeres, and atherosclerosis
• Aging and plasminogen activator inhibitor-1 (PAI-1) regulation
• Adenosine-mediated cardioprotection in the aging myocardium
• Aging hearts and vessels
• Vascular genetic factors and human longevity
• Cardiovascular fitness, cortical plasticity, and aging

  back

Cellular Cholesterol Metabolism and Trafficking and Apoptosis

• Sterol homeostasis in the budding yeast
• Requirement of sterols in the life cycle
• Molecular mechanisms of cholesterol absorption and transport in the intestine
• Cholesterol homeostasis in neurons and glial cells
• Caveolin, cholesterol, and lipid bodies
• New aspects of cellular sterol metabolism and transport

  back

Aging hearts and vessels

• Vascular consequences of menopause and hormone therapy
• Sympathetic neuronal regulation of the heart in aging and heart failure
• Protection in the aged heart
• Mitochondrial function and myocardial aging
• Inflammatory markers and cardiovascular health in older adults
• Gene expression profiling studies of aging in cardiac and skeletal muscles
• Evolution and modulation of age-related medial elastocalcinosis
• Endothelial aging
• Aging-associated changes in cardiac gene expression
• Aging, telomeres, and atherosclerosis
• Aging and plasminogen activator inhibitor-1 (PAI-1) regulation
• Adenosine-mediated cardioprotection in the aging myocardium
• Aging hearts and vessels

  back

New approaches to hypertension management

• Use of noninvasive hemodynamics in hypertension management
• Systolic blood pressure does not reliably identify vasoactive status in chronic heart failure
• Reproducibility of impedance cardiography parameters in outpatients with clinically stable coronary artery disease
• Prognostic value of hemodynamic findings from impedance cardiography in hypertensive stroke
• Noninvasive hemodynamic profiles in hypertensive subjects
• Noninvasive hemodynamic assessment of the effect of mean arterial pressure on the amplitude of pulse pressure
• Hypertension as a hemodynamic disease
• Diagnostic ability of B-type natriuretic peptide and impedance cardiography
• New approaches to hypertension management

  back

Lipid

• Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells
• The Biosynthetic Pathway for Cholesterol
• Leptin receptor action and mechanisms of leptin resistance
• Leptin induces hypertrophy via p38 mitogen-activated protein kinase in rat vascular smooth muscle cells
• Function of prokaryotic and eukaryotic ABC proteins in lipid transport
• FAT CELLS
• Effects of cilostazol on lipid and fatty acid metabolism
• Dyslipidemia-Type 2 Diabetes and the Metabolic Syndrome
• Dyslipidemia-The Role of the Hospitalist in Guideline Adherence and In-Hospital Initiation of Therapy
• Dyslipidemia-Raising the Profile While Lowering the Levels
• Dyslipidemia-National Cholesterol Education Program Guidelines and Supporting Evidence
• Dyslipidemia-In-Hospital Initiation of Lipid-Lowering Therapy
• Dyslipidemia
• Direct Measurement of Nitric Oxide and Oxygen Partitioning into Liposomes and Low Density Lipoprotein
• Dietary fatty acids and the haemostatic system

  back

GATA Transcription Factors in Heart

• Using the zebrafish model to study GATA transcription factors
• The roles of GATA-4,-5 and-6 in vertebrate heart development
• Regulation of GATA gene expression during vertebrate development
• Gene expression regulation and domain function of hematopoietic GATA factors
• GATA1 in normal and malignant hematopoiesis
• GATA factors in Drosophila heart and blood cell development
• Coregulation of GATA factors by the Friend of GATA (FOG) family of multitype zinc finger proteins
• GATA transcription factors in heart and blood cell development and disease

  back

Physiol-Resistance Arteries

• Toward functional genomics of flow-induced outward remodeling of resistance arteries
• Shed membrane microparticles from circulating and vascular cells in regulating vascular function
• Peroxisome proliferator-activated receptors and cardiovascular remodeling
• Marriage of resistance and conduit arteries breeds critical limb ischemia
• In vivo functional NMR imaging of resistance artery control
• Cytokines and vascular reactivity in resistance arteries
• Control of blood vessel structure
• cell-RhoA and resistance artery remodeling
• highlights of the 8th International Symposium on Resistance Arteries

  back

PDGF

• The PDGF family
• Regulation of PDGF and its receptors in fibrotic diseases
• Platelet-derived growth factor
• PDGF signaling in cells and mice
• PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases
• PDGF and cardiovascular disease
• Insight into the physiological functions of PDGF through genetic studies in mice
• ca-PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

  back

Beta-Blockers and Heart Failure

• The Effects of Beta Blockers on Morbidity and Mortality in Heart Failure
• Sex-Related Differences in Heart Failure and Beta-Blockers
• Pharmacokinetics and Pharmacodynamics of Beta Blockers in Heart Failure
• B-Type Natriuretic Peptide and the Right Heart
• Biologic Rationale for the Use of Beta-Blockers in the Treatment of Heart Failure
• Beta-Blockers in Heart Failure
• Beta Blockers as Anti-Arrhythmic Agents
• Beta Blocker Therapy in African American Patients with Heart Failure
• Beta Blocker Therapy After Acute Myocardial Infarction in Patients with Heart Failure
• Beta-Blockers and Heart Failure-Editorial1

  back

Cardiovascular risk

• Treating to hypertension targets
• Secondary prevention clinics- improving quality of life and outcome
• Questions and answer session
• Primary prevention of cardiovascular disease- managing hypertension and hyperlipidaemia
• New evidence in hypertension and hyperlipidaemia
• Meeting the challenge of cardiovascular care in the new National Health Service
• Managing the cost of cardiovascular prevention in primary care
• Helping patients to improve self management of diabetes
• Engaging patients in managing their cardiovascular health
• Diabetes- preventing coronary heart disease in a high risk group
• Applying the evidence- guidelines in primary care
• Cardiovascular risk

  back

Senescent Heart

• What Do Hormones Have to Do with Aging
  
• The Extent and Significance of Telomere Loss with Age
  
• Senescence Marker Protein-30 as a Novel Antiaging Molecule
  
• Response of the Senescent Heart to Stress
  
• Proinflammatory Phenotype of Senescent Cells
  
• Mechanism of Telomere Shortening by Oxidative Stress
  
• Mechanism of Superoxide-Mediated Damage Relevance to Mitochondrial Aging
  
• Genomic Instability, Aging, and Cellular Senescence
  
• Functional Efficiency of the Senescent Cells
  
• Effects of Age and Caloric Restriction on Brain Neuronal Cell Death
  
• Differential Regulation of Telomerase in Endothelial Cells by Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor-A
  
• Delaying the Mitochondrial Decay of Aging
  
• Cardiovascular Disease Delay in Centenarian Offspring
  
• Apolipoprotein E Genotype and Age at Menopause
  
• Aging, Exercise, and Cardioprotection
  
• Aging of Cardiac Myocytes in Culture
  
• Acute Coronary Syndrome, Comorbidity, and Mortality in Geriatric Patients
  

  back

Hypertrophic pathways

• Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy
  
• Network integration of the adrenergic system in cardiac hypertrophy
  
• Negative regulators of cardiac hypertrophy
  
• Myocyte hypertrophy and apoptosis
  
• Interference of antihypertrophic molecules and signaling pathways with the Ca2+–calcineurin–NFAT cascade
  
• Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system
  
• Human cardiac inwardly rectifying current IKir2.2 is upregulated by activation of protein kinase A
  
• Gender modulates cardiac phenotype development in genetically modified mice
  
• Fibroblast growth factor 2 isoforms and cardiac hypertrophy
  
• Cross-talk of opioid peptide receptor and-adrenergic receptor signalling in the heart
  
• cross-talk between integrins and growth factor receptors
  
• Calcineurin–NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs
  
• Atrial natriuretic peptide modulates the hyperpolarization-activated current (If) in human atrial myocytes
  
• Adaptive and maladaptive hypertrophic pathways-points of convergence and divergence
  

  back

Scaffolding and docking proteins

• The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease
  
• Scaffold proteins and assembly of multiprotein signaling complexes
  
• Macromolecular complexes regulating cardiac ryanodine receptor function
  
• Ions and channels-new answers to old questions
  
• Interaction of G with RACK1 and other WD40 repeat proteins
  
• Heart failure-how important is cellular sequestration
  
• Cardiac ion channel expression and regulation
  
• 2-Adrenergic receptor signaling complexes in cardiomyocyte caveolae-lipid rafts
  
• Scaffolding and docking proteins of the heart, an introduction
  

  back

Matrix Metalloproteinases

• Regulation of Matrix Metalloproteinases by Cytokines and Reactive Oxygen
  
• Possible Interactions Between Inflammatory Mediators and MMP-TIMP System
  
• Pathways of Induction by Bioactive Molecules
  
• New Insights into Myocardial Remodeling
  
• MMP Induction and Inhibition in Myocardial Infarction
  
• Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery
  
• Interaction Between Matrix Metalloproteinase Activity and Adverse Myocardial Remodeling
  

  back

Free radicals and redox signalling in cardiovascular disease

• SOXF-redox mediators of vascular smooth muscle cell growth
  
• Novel NAD(P)H oxidases in the cardiovascular system
  
• Free radical production by dysfunctional eNOS
  
• Free radicals and redox signalling in cardiovascular disease2
  
• Free radicals and redox signalling in cardiovascular disease1
  
• Free radicals and redox signalling in cardiovascular disease
  

  back

Carvedilol

• Ventricular remodeling in heart failure and the effect of-blockade
  
• Tolerability of carvedilol in heart failure
  
• the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study
  
• Special considerations for carvedilol use in heart failure
  
• Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes
  
• Role of carvedilol in atrial fibrillation-insights from clinical trials
  
• Reappraisal of-blocker therapy in the acute and chronic post–myocardial infarction period
  
• Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure
  
• Practical guidelines to optimize effectiveness of-blockade in patients postinfarction and in those with chronic heart failure
  
• Pharmacology of carvedilol
  
• Commentary on the Carvedilol or Metoprolol European Trial
  
• Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial
  
• Cardiac remodeling in coronary artery disease
  
• -blockers in hypertension
  
• Advantages of a third-generation-blocker in patients with diabetes mellitus
  
• Carvedilol
  

  back

pulmonary arterial hypertension

• Prostanoid therapy for pulmonary arterial hypertension
  
• Primary pulmonary arterial hypertension
  
• Pathologic assessment of vasculopathies in pulmonary hypertension
  
• Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension
  
• look to the future
  
• Interventional and surgical modalities of treatment for pulmonary arterial hypertension
  
• Genetic basis of pulmonary arterial hypertension
  
• Endothelin receptor antagonists in pulmonary arterial hypertension
  
• End points and clinical trial designs in pulmonary arterial hypertension
  
• Diagnosis and differential assessment of pulmonary arterial hypertension
  
• Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension
  
• Clinical classification of pulmonary hypertension
  
• Cellular and molecular pathobiology of pulmonary arterial hypertension
  
• pulmonary arterial hypertension－introducation
  
• Pulmonary Arterial Hypertension
  
• Pulmonary Arterial Hypertension
  
• Bosentan therapy for pulmonary arterial hypertension
  
• High-altitude pulmonary hypertension
  
• End points in pulmonary arterial hypertension
  

  back

Management of atrial fibrillation

• Percutaneous Catheter Ablation Procedures for the Treatment of Atrial Fibrillation
  
• Minimally Invasive Surgery for Atrial Fibrillation
  
• Microwave Energy Ablation in Patients with Permanent Atrial Fibrillation
  
• Atrial Ablation for the Surgical Treatment of Atrial Fibrillation
  
• Alternative Energy Sources for Surgical Atrial Ablation
  
• MANAGEMENT OF ATRIAL FIBRILLATION
  
• Role of oral anticoagulation in management of atrial fibrillation
  

  back

Nutrition in CVD

• Wasting and the substrate-to-energy controlled pathway
  
• Oral amino acid administration in patients with diabetes mellitus
  
• Nutritional supplementation with mixed essential amino acids enhances myocyte survival, preserving mitochondrial functional capacity during ischemia-reperfusion injury
  
• Metabolic effects of orally administered amino acid mixture in elderly subjects with poorly controlled type 2 diabetes mellitus
  
• Inadequate nutritional intake for daily life activity of clinically stable patients with chronic heart failure
  
• Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus
  
• Effect of amino acid mixture on the isolated ischemic heart
  
• Early myocardial dysfunction in the diabetic heart-current research and clinical applications
  
• Diabetic cardiomyopathy-A metabolic perspective
  
• Amino acids
  
• Nutritional supplements in the treatment of cardiovascular disease
  

  back

Neurohumoral control of cardiovascular function

• Neurohumoral control of cardiovascular function-from genes to physiology
  
• Viral vectors as tools for studies of central cardiovascular control
  
• The origin of sympathetic outflow in heart failure
  
• Targeting neuronal nitric oxide synthase with gene transfer to modulate cardiac autonomic function
  
• role of the renin¨Cangiotensin system in malignant vascular injury affecting the systemic and cerebral circulations
  
• Redox signaling in central neural regulation of cardiovascular function
  
• Nitric oxide and homeostatic control
  
• Functional genomics as an emerging strategy for the investigation of central mechanisms in experimental hypertension
  
• Developmental gene control of brainstem function
  
• Designing gene delivery vectors for cardiovascular gene therapy
  
• Deciphering the mechanisms of homeostatic plasticity in the hypothalamo-neurohypophyseal system
  
• Cardiovascular regulation of supraoptic neurons in the rat
  
• Adenovirus-mediated gene transfer into the brain stem to examine cardiovascular function
  

  back

Endothelium-dependent hyperpolarizations

• Endothelium-dependent hyperpolarizations
  
• Prostacyclin and endothelium-dependent hyperpolarization
  
• Potassium and potassium clouds in endothelium-dependent hyperpolarizations
  
• obligatory link-role of gap junctional communication in endothelium-dependent smooth muscle hyperpolarization
  
• Hydrogen peroxide as an endothelium-derived hyperpolarizing factor
  
• EDHF-new therapeutic targets
  
• Cytochrome P450 epoxygenases as EDHF synthase
  
• 14,15-EET analogs-characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries
  

  back

Myocardial reperfusion injury

• Myocardial reperfusion injury
• The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction
• Selective retroinfusion of GSH and cariporide attenuates myocardial ischemia¨Creperfusion injury
• Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium
• Role of clinical pathologies in myocardial injury following ischaemia and reperfusion
• Role of apoptosis in reperfusion injury
• Protein kinase activation and myocardial ischemia-reperfusion injury
• Poly(ADP-ribose) polymerase activation in the reperfused myocardium
• Nitric oxide in myocardial ischemia-reperfusion injury
• New directions for protecting the heart against ischaemia¨Creperfusion injury
• New concepts in reactive oxygen species and cardiovascular reperfusion physiology
• Molecular determinants of responses to myocardial ischemia-reperfusion injury
• Limited effects of post-ischemic NHE blockade on [Na+]i and pHi in rat hearts explain its lack of cardioprotection
• Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury
• Inhibition of Rho-kinase protects the heart against ischemia-reperfusion injury
• Gap junction-mediated spread of cell injury and death during myocardial ischemia¨Creperfusion
• Diazoxide causes early activation of cardiac sarcolemmal KATP channels during metabolic inhibition by an indirect mechanism
• cardioprotection-The first minutes of reperfusion-a window of opportunity for cardioprotection
• cardioprotection-Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection

  back

N-terminal proBNP

• Use of NT-proBNP in routine testing and comparison to BNP
• NT-proBNP in unstable coronary artery disease-experiences from the FAST, GUSTO IV and FRISC II trials
• NT-proBNP in severe chronic heart failure
• NT-proBNP in heart failure-therapy decisions and monitoring
• NT-proBNP and the diagnosis of heart failure-a pooled analysis of three European epidemiological studies
• NT-proBNP and BNP-biomarkers for heart failure management
• N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction
• N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function
• N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis
• Natriuretic peptides for risk stratification of patients with acute coronary syndromes
• Natriuretic peptides for heart failure
• Essential biochemistry and physiology of (NT-pro)BNP
• Can natriuretic peptides be used for the diagnosis of diastolic heart failure
• Brain and other natriuretic peptides-molecular aspects
• Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure
• Application of NT-proBNP and BNP measurements in cardiac care
• Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay

  back

Acute coronary syndrome

• Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome
• Prognostic relations between inflammatory markers and mortality in diabetic patients
• glycoprotein IIb-IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes
• ST segment elevation myocardial infarction
• unstable angina and non-ST segment elevation myocardial infarction
• the struggle for the best in risk stratification and therapy
• Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina
• Acute statin treatment in reducing risk after acute coronary syndrome
• The new directions in the understanding and management of acute coronary syndromes
• Should intensive cholesterol lowering play a role in the management of acute coronary syndromes
• Role of plaque rupture in acute coronary syndromes
• Relation between endothelial dysfunction and the acute coronary syndrome-implications for therapy
• Medical therapy of unstable angina and non_q-wave myocardial infarction
• Introduction
• Exploring new strategies for the management of acute coronary syndromes
• Coronary artery injury and the biology of atherosclerosis-inflammation, thrombosis, and stabilization

  back

Women's Ischemic Syndrome Evaluation

• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Executive Summary
• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Perspective New Frontiers in Detection of Ischemic Heart Disease in Women
• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Section 1 Diagnosis of Stable Ischemia and Ischemic Heart Disease
• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Section 2 Stable Ischemia: Pathophysiology and Gender Differences
• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Section 3 Diagnosis and Treatment of Acute Cardiac Ischemia: Gender Issues
• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Section 4 Lessons From Hormone Replacement Trials
• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Section 5 Gender-Related Risk Factors for Ischemic Heart Disease
• Women's Ischemic Syndrome Evaluation-Current Status and Future Research Directions-Section 6 Key Messages About Acute Ischemic Heart Disease in Women and Recommendations for Practice

  back

Antiplatelet And Anticoagulant Agents In Cardiovascular Disease

• Tissue Factor In Acute Coronary Syndromes
• The Role Of The Tissue Factor-Thrombin Pathway In Cardiac Ischemia-Reperfusion Injury
• The Present And Future Of Heparin, Low Molecular Weight Heparins, Pentasaccharide, And Hirudin For Venous Thromboembolism And Acute Coronary Syndromes
• Targeting Tissue Factor As An Antithrombotic Strategy
• Role Of Platelets In The Pathophysiology Of Acute Coronary Syndrome
• Rfviiai In Acute Coronary Syndromes
• P2y12,-New Platelet Adp Receptor-Target Of Clopidogrel
• Orally Active Direct Thrombin Inhibitors
• Low-Dose Aspirin For Primary Prevention Of Cardiovascular Disease
• Gpiib-Iiia Antagonists And Other Anti-Integrins
• Combined Antithrombotic Therapy For Acute Coronary Syndrome
• Aspirin And Other Cyclooxygenase Inhibitors
• Antithrombotic Drugs In Vascular Medicine-A Historical Perspective
• Antiplatelet And Anticoagulant Agents In Cardiovascular Disease
• Effect of Antiplatelet and Anticoagulant Agents on Risk of Hospitalization for Bleeding Among a Population of Elderly Nursing Home Stroke Survivors

  back

Sympathetic Neural Mechanism In Cardiovascular Control

• Vestibular Activation Of Sympathetic Nerve Activity
• Sympathetic Vasodilation In Human Muscle
• Effects Of Heat Stress On Baroreflex Function In Humans
• Central Angiotensin Modulation Of Baroreflex Control Of Renal Sympathetic Nerve Activity
• Arousal Increases Baroreflex Inhibition Of Muscle Sympathetic Activity
• Alterations Of Sympathetic Control By Space Travel
• Why Do Human Postganglionic Neurones Primarily Only Fire Once During-Sympathetic Burst
• Transmission Of Signals Through Sympathetic Ganglia-Modulation, Integration
• Sympathetic Nerve Activity And Neurotransmitter Release In Humans
• Neurophysiological Analysis Of Target-Related Sympathetic Pathways
• Medullary And Supramedullary Mechanisms Regulating Sympathetic Vasomotor Tone
• Functional Organization Of Peripheral Vasomotor Pathways
• Are Pre-Ganglionic Neurones Recruited In-Set Order